Adalimumab in the management of Behçet’s disease

Figures & data

Table 1 Ocular involvement of BD treated with adalimumab

Case	Age/sex	Study design	Previous IFX use	IFX efficacy	Follow-up duration (mo)	Outcomes	Previous therapies	Maintenance therapies	References
1	28/M	Pro	Yes	IFX failure	25	Remission	IFX, Ste, CyA	ADA, CyA	Olivieri et al^Citation25
2	55/M		Yes	IFX failure	14	Remission	IFX, Ste, CyA	ADA, CyA
3	33/M		Yes	IFX failure	3	NR	IFX, Ste, CyA	ADA, Ste, CyA
4	39/M		Yes	IFX failure	7	Remission	IFX, Ste, CyA	ADA, CyA
5	38/M	Pro	Yes	Effective	Unknown	Remission	IFX, Ste, CyA, AZA	ADA monotherapy	Adan et al^Citation26
6	26/F		Yes	Effective	Unknown	Remission	IFX, Ste, CyA	ADA monotherapy
7	34/M				12	Remission	ETN, Ste, MTX, CyA	Unknown	Diaz-Llopis et al^Citation27
8	35/M				12	Remission	ETN, Ste, CyA, AZA	Unknown
9	28/M		Yes	IFX failure	12	Remission	IFX, Ste, CyA, MTX	Unknown
10	41/F	Pro	Yes	IFX failure	23	Remission	IFX, Ste, CyA	ADA, Col	Catala et al^Citation28
11	42/F		No		30	Remission	Ste, CyA, AZA	ADA, AZA
12	44/F		Yes	IFX failure	41	Remission	IFX, Ste, CyA	ADA, Ste
13	46/M		No		12	Remission	Ste, CyA, AZA	ADA, Ste
14	44/M		No		15	Remission	Ste, CyA, AZA, Col	ADA, Ste
15	27/M	Retro	No		9	Remission	Ste, CyA, Col	ADA, Ste, Col	Bawazeer et al^Citation30
16	35/M		No		14	Remission	Ste, AZA, Col	ADA, Col
17	30/M		No		10	Remission	Ste, AZA, Col	ADA, AZA, Col
18	24/M		No		12	Remission	Ste, CyA, Col	ADA, Ste, Col
19	33/M		No		15	Remission	Ste, AZA, Col	ADA, AZA, Col
20	19/M		No		11	Remission	Ste, AZA	ADA, Ste
21	22/M		No		8	Remission	Ste, CyA, Col	ADA, Ste, CyA, Col
22	38/M		No		4	NR	Ste, CyA, Col	ADA, Ste, CyA, Col
23	26/M		No		9	Remission	Ste, AZA, Col	ADA, Ste, Col
24	30/M		Yes	IFX failure	10	Remission	IFX, MTX	ADA, MTX
25	28/M		No		17	Remission	Ste, CyA, Col	ADA, Ste, Col
26	15/M	Retro	Yes	IFX failure	22	Remission	IFX, Ste, AZA	ADA, Ste, AZA	Interlandi et al^Citation31
27	33/M		Yes	IFX failure	26	Remission	IFX, Ste, AZA	ADA, AZA
28	20/F		No		6	Remission	Ste, CyA	ADA monotherapy
29	26/M		Yes	IFX failure	23	Remission	IFX, Ste, CyA	ADA monotherapy
30	23/M		No		31	Remission	Ste, CyA	ADA monotherapy
31	30/M		Yes	IFX failure	18	Remission	IFX, Ste, AZA	ADA monotherapy
32	31/M		Yes	IFX failure	13	NR	IFX, Ste, CyA	ADA, Ste, IFN
33	26/M		No		30	Remission	Ste, CyA	ADA monotherapy
34	16/M		No		18	Remission	Ste, CyA	ADA monotherapy
35	25/M		Yes	IFX failure	18	Remission	IFX, Ste, AZA	ADA, Ste
36	39/M		Yes	IFX failure	38	Remission	IFX, Ste, CyA	ADA, Ste, CyA
37	8/M		Yes	IFX failure	8	Remission	IFX, Ste, AZA	ADA, Ste, CyA
38	41/F	Case R	Yes	Effective	8	Remission	IFX, Ste, CyA, IVCY	ADA monotherapy	Mushtaq et al^Citation33
39	28/M		Yes	Effective	21	Remission	IFX, Ste, CyA, IVCY, AZA, MTX	ADA monotherapy
40	21/F		Yes	Effective	18	Remission	IFX, Ste, CyA, MTX, AZA, MMF	ADA, Ste
41	40/M	Case R	Yes	Effective	19	PR	IFX, Ste, MTX	ADA, Ste	van Laar et al^Citation29
42	36/M		Yes	Effective	14	PR	IFX, Ste	ADA, Ste
43	26/M	Case R	Yes	IFX failure	30	Remission	IFX, Ste, CyA	ADA monotherapy	Leccese et al^Citation32
44	42/F	Case R	Yes	AE	6	Remission	IFX	ADA montherapy	Takase et al^Citation34
45	55/F	Case R	No		26	Remission	Ste, CyA, MTX	ADA, MTX	Callejas-Rubio et al^Citation35
46	53/M		No		12	Remission	ETN, Ste, CyA, MTX	ADA, MTX
47	38/M		No		6	Remission	Ste, CyA, MTX	ADA, MTX

Abbreviations: ADA, adalimumab; AE, adverse event; AZA, azathioprine; Case R, case report; Col, colchicine; CyA, cyclosporine A; ETN, etanercept; IFX, infliximab; IVCY, intravenous cyclophosphamide; MMF, mycophenolate mofetil; mo, months; MTX, methotrexate; NR, non-remission; PR, partial remission; Pro, prospective; Retro, retrospective; Ste, steroid.

Table 2 Intestinal Behçet’s disease treated with adalimumab

Case	Age/sex	Study design	Previous IFX use	IFX efficacy	Follow-up duration (mo)	Outcomes	Previous therapies	Maintenance therapies	References
1	29/M	Case R	Yes	Effective	36	Remission	IFX	ADA, AZA, 5-ASA, Ste	Chung^Citation50
2	21/F	Case R	No		>2	Remission	(–)	ADA monotherapy	De Cassan et al^Citation52
3	17/M		No		12	Remission	Col, Ste	ADA monotherapy
4	46/F	Case R	No		18	PR	AZA, MTX	ADA monotherapy	Aikawa et al^Citation51
5	34/M	Case R	Yes	Effective	24	Remission	IFX, Ste, MTX, CyA	ADA, 5-ASA, Ste	Van Laar et al^Citation29
6	30/F	Case R	Yes	Effective	22	Remission	IFX, AZA	ADA monotherapy	Ariyachaipanich et al^Citation53
7	63/F	Case R	Yes	Effective	3	Remission	IFX, Ste	ADA monotherapy	Shimizu et al^Citation54

Abbreviations: 5-ASA, 5-aminosalicylic acid; ADA, adalimumab; AZA, azathioprine; Case R, case report; Col, colchicine; CyA, cyclosporine A; IFX, infliximab; mo, months; MTX, methotrexate; PR, partial remission; Ste, steroid.

Table 3 Neuro-Behçet’s disease treated with adalimumab

Case	Age/sex	Study design	Previous IFX use	IFX efficacy	Follow-up duration (mo)	Outcomes	Previous therapies	Maintenance therapies	References
1	41/F	Pro	Yes	IFX failure	23	Remission	IFX, Ste, CyA	ADA, Col	Catala et al^Citation28
2	39/M	Case R	Yes	IFX failure	12	Remission	IFX, Ste, CyA	ADA, Ste	Olivieri et al^Citation25
3	56/M		Yes	IFX failure	6	NR	(–)	ADA montherapy
4	41/F		Yes	IFX failure	6	NR	(–)	ADA montherapy
5	36/M	Case R	Yes	Effective	24	Remission	IFX, CyA, IVCY	ADA montherapy	Belzunegui et al^Citation56
6	12/F	Case R		No	12	Remission	Ste, MMF, AZA	ADA montherapy	Robinson et al^Citation57
7	41/F	Case R	Yes	Effective	13	Remission	Ste, CyA	ADA, Ste	Van Laar et al^Citation29
8	43/F	Case R	Yes	Effective	6	Remission	Ste	ADA, Ste

Abbreviations: ADA, adalimumab; AZA, azathioprine; Case R, case report; Col, colchicine; CyA, cyclosporine A; IFX, infliximab; IVCY, intravenous cyclophosphamide; MMF, mycophenolate mofetil; mo, months; NR, non-remission; Pro, prospective; Ste, steroid.

OlivieriILeccesePD’AngeloSEfficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximabClin Exp Rheumatol20112967S54S5721968237

 PubMedGoogle Scholar

AdánAHernandezVOrtizSEffects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusionsInt Ophthalmol201030557758120490893

 PubMed Web of Science ®Google Scholar

Diaz-LlopisMGarcía-DelpechSSalomDAdalimumab therapy for refractory uveitis: a pilot studyJ Ocul Pharmacol Ther200824335136118476805

 PubMed Web of Science ®Google Scholar

CataláJCFernandezCCCidAREfficacy of adalimumab in Behçet’s disease. Description of 6 casesRhematol Clin201174258261

 Google Scholar

BawazeerARaffaLHClinical experience with adalimumab in the treatment of ocular Behçet diseaseOcul Immunol Inflamm201018322623220482404

 PubMed Web of Science ®Google Scholar

InterlandiELeccesePOlivieriIAdalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up studyClin Exp Rheumatol20143284S58S6225005224

 PubMedGoogle Scholar

MushtaqBSaeedTSitunayakeRDMurrayPIAdalimumab for sight-threatening uveitis in Behçet’s diseaseEye200721682482516601736

 PubMed Web of Science ®Google Scholar

van LaarJAMissottenTvan DaelePLJamnitskiABaarsmaGSvan HagenPMAdalimumab: a new modality for Behçet’s disease?Ann Rheum Dis200766456556617124248

 PubMed Web of Science ®Google Scholar

LeccesePLatanzaLD’AngeloSPadulaAOlivieriIEfficacy of switching to adalimumab in a patient with refractory uveitis of Behçet’s disease to infliximabClin Exp Rheumatol20112967S9321813069

 PubMedGoogle Scholar

TakaseKOhnoSIdeguchiHUchioETakenoMIshigatsuboYSuccessful switching to adalimumab in an infliximab-allergic patient with severe Behçet’s disease-related uveitisRheumatol Int201131224324519816689

 PubMed Web of Science ®Google Scholar

Callejas-RubioJLSánchez-CanoDSerranoJLOrtego-CentenoNAdalimumab therapy for refractory uveitis: a pilot studyJ Ocul Pharmacol Ther200824661361419049264

 PubMed Web of Science ®Google Scholar

ChungSHIntestinal Behçet’s disease appearing during treatment with adalimumab in a patient with ankylosing spondylitisWorld J Gastroenterol201319325389539223983446

 PubMed Web of Science ®Google Scholar

De CassanCDe VroeyBDussaultCHachullaEBucheSColombelJ-FSuccessful treatment with adalimumab in a familial case of gastrointestinal Behçet’s diseaseJ Crohns Colitis20115436436821683309

 PubMed Web of Science ®Google Scholar

AikawaNEGonçalvesCSilvaCAGonçalvesCBonfáEde CarvalhoJFLate response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet’s diseaseRheumatol Int20093181097109920012049

 PubMed Web of Science ®Google Scholar

AriyachaipanichABerkelhammerCNicolaHIntestinal Behçet’s disease: maintenance of remission with adalimumab monotherapyInflamm Bowel Dis200915121769177119177427

 PubMed Web of Science ®Google Scholar

ShimizuYTakedaTMatsumotoRClinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Behçet diseaseNihon Shokakibyo Gakkai Zasshi20121095774780 Japanese22688103

 PubMedGoogle Scholar

BelzuneguiJLópezLPaniaguaIIntxaustiJJMaízOEfficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet’s diseaseClin Exp Rheumatol20082650S133S13419026138

 PubMedGoogle Scholar

RobinsonABGallentineWBRabinovichCEPediatric neuro-Behçet’s disease responsive to adalimumabPediatr Neurol201043429129320837311

 PubMed Web of Science ®Google Scholar